Amgen Licenses Rights To Multiple Myeloma Drug

Thousand Oaks-based Amgen and Boehringer Ingelheim said on Thursday that Amgen has acquired the global development and commercial rights for an immuno-oncology drug for treating multiple myeloma. The two said Amgen acquired the rights from Boehringer Ingelheim for BI 836909 (AMG 420), a bispecific T cell engager (BiTE) that targets B-cell maturation antigen (BCMA), a potential target for multiple myeloma. The compound is currently in Phase I studies. The two said the drug was originally licensed to Boehringer Ingelheim by Micromet, before Amgen acquired Micromet in 2012. Financial details of the deal were not announced.